Myeloma Condition Information/Myeloma General Information

Stage 2 Multiple Myeloma Prognosis: Fear, Hope, and Understanding Survival Rates

Medically reviewed by Fatima Sharif, MBBS, FCPS

Written by Jennifer Berger, Ph.D.

Updated on October 14, 2026

Feel better informed on myeloma and get real support from your community.

Join

Key Takeaways

Multiple myeloma is a type of blood cancer that affects plasma cells, and doctors use the Revised International Staging System (R-ISS) to classify it into three stages based on blood test results, protein levels, and genetic changes in the cancer cells.
Stage 2 multiple myeloma falls in the middle of the three stages, meaning it is more advanced than stage 1 but not as severe as stage 3. A person's prognosis can depend on many factors, including their overall health, age, how the cancer responds to treatment, and the specific features of their myeloma cells.
Talking with your cancer care team is an important step in understanding what your diagnosis means for you personally, and if you face barriers to getting the care you need, asking for a referral to a specialist, connecting with a patient navigator, or exploring clinical trials may help you access more options.

View all takeaways

What Are the 3 Stages of Multiple Myeloma?

Transcript

00:00:00:00 - 00:00:22:11
Voiceover
When it comes to multiple myeloma, understanding the three stages can help you feel more informed. Let's break down each stage and how myeloma may progress. Multiple myeloma is a type of blood cancer that develops in plasma cells, which are a key part of your immune system. Doctors use the Revised International Staging System, or R-ISS, to classify the disease into three stages.

00:00:22:14 - 00:00:48:29
Voiceover
These stages are based on blood test results showing protein levels, genetic changes in cancer cells, and other factors. Let's start with stage 1 multiple myeloma, the earliest stage. At this point, some people may not even have symptoms yet. Testing shows minimal signs of myeloma and low levels of cancer cells. You may be recommended to start treatment when you develop symptoms, or certain test results show a high risk for progression. In stage 2 multiple myeloma,

00:00:49:01 - 00:01:13:26
Voiceover
you might have symptoms like bone pain, fatigue, and frequent infections. Here, test results show the disease is more advanced than stage 1, but not as severe as stage 3. People with stage 2 multiple myeloma may need more intensive treatments than people with stage 1. Stage 3 multiple myeloma is the most advanced stage. Protein markers in the blood are very high, and genetic changes in cancer cells indicate aggressive disease.

00:01:13:28 - 00:01:37:00
Voiceover
Symptoms can include severe bone damage, anemia, and poor kidney function. How fast does multiple myeloma progress? That depends on details about your myeloma cells and your individual health. Stage 1 may remain stable for years, while stage 3 tends to progress more quickly. No matter your stage, knowing your treatment options and sticking to your regimen can make a big difference.

00:01:37:03 - 00:01:47:22
Voiceover
It's also important to discuss your symptoms and side effects with your doctors and get care to help you feel your best. Learn more and connect at MyMyelomaTeam.com.

A diagnosis of stage 2 multiple myeloma can bring a lot of questions, including what it may mean for your future. Stage 2 means the cancer isn’t in the earliest stage, but it is also not the most advanced stage.

Your prognosis and life expectancy can depend on your current health, age, and test results, as well as how well the cancer responds to treatment. Understanding these factors can help you make sense of what stage 2 may mean for you.

What Is Stage 2 Multiple Myeloma?

Stage 2, also written stage II, is the middle of the three stages of multiple myeloma in the Revised International Staging System (R-ISS). Unlike many other cancers, multiple myeloma isn’t staged mainly by how far it has spread. Instead, doctors use blood tests and changes in the myeloma cells to help understand how the disease may behave.

🗳️ Do you or a loved one have stage 2 multiple myeloma?

Yes, I do.

Yes, a loved one does.

I or a loved one may have stage 2.

No, I’m learning more about it.

The R-ISS looks at four main factors:

Beta-2 microglobulin — A protein measured in the blood or urine. Higher levels may be linked to more advanced disease.
Albumin — A protein made by the liver and measured in the blood. Lower levels may be linked to a less favorable prognosis (expected outcome).
Lactate dehydrogenase (LDH) — An enzyme measured in the blood. High LDH levels may be linked to faster-growing myeloma.
Chromosome changes — Myeloma cells can have changes in their chromosomes, which carry genetic information. Some chromosome changes, such as missing or rearranged pieces, can make the myeloma more likely to grow quickly or be harder to treat.

There isn’t a single set of results that defines stage 2, so different combinations of these factors can lead to a stage 2 multiple myeloma diagnosis.

In 2022, researchers introduced the Second Revision of the International Staging System (R2-ISS), which builds on the R-ISS while incorporating new risk scoring criteria. This system is increasingly being adopted in clinical practices but is not yet considered the standard diagnostic system.

What Is the Prognosis for Multiple Myeloma?

Your doctor may use the R-ISS to estimate your stage 2 prognosis based on blood test results and certain changes in the myeloma cells.

In the study that established the R-ISS, about 62 percent of people with stage 2 multiple myeloma were alive five years after diagnosis.

However, this number is based on people treated years ago, so it may not reflect outcomes with newer treatments. Also, this study described a group of people and can’t predict exact outcomes for a single person.

Treatments for Stage 2 Multiple Myeloma

There is no treatment used only for stage 2 multiple myeloma. For all active myeloma, doctors choose treatment methods based on features of the cancer and whether the person can have a stem cell transplant.

Treatment plans may include:

Induction therapy — This is the first phase of treatment. Most people receive three or four medicines together to reduce the amount of myeloma in the body.
Autologous stem cell transplant — Some people may have a stem cell transplant after their first few months of treatment. “Autologous” means the transplant uses your own stem cells.
Maintenance therapy — After initial treatment or a transplant, some people take a long-term medicine, often at a lower intensity, to help keep the myeloma under control.
Bone treatment — Medicines such as bisphosphonates or denosumab (Xgeva) may help protect bones and lower the risk of fractures and other bone problems. This is a supportive treatment for myeloma and does not destroy cancer cells.

If myeloma comes back or stops responding to treatment, doctors may try other medicines or treatments, such as CAR T-cell therapy or T-cell engagers.

How Long Do People Live With Stage 2 Multiple Myeloma?

Another way researchers measure survival is median overall survival. This is the length of time at which half of the people in a study are still alive.

In the original R-ISS study, median overall survival was 83 months for people with stage 2 multiple myeloma — about seven years. This does not mean that someone with stage 2 myeloma will live for exactly that amount of time. Some people in the study lived for less time, while others lived much longer.

Why Stage 2 Life Expectancy Can Be Hard To Predict

Life expectancy estimates for stage 2 multiple myeloma are based on people who were diagnosed and treated in the past. Since then, multiple myeloma treatments have continued to change, with more treatment options becoming available.

This means older survival numbers may not fully reflect what someone diagnosed today can expect. Some people live with multiple myeloma for many years, often going through different treatments as the disease changes over time.

Your cancer care team can help put survival statistics in context based on your specific disease and treatment plan.

Race, Access to Care, and Multiple Myeloma Survival

Studies have found differences in diagnosis, treatment access, and outcomes among certain racial and ethnic groups.

A U.S. systematic review found that, after accounting for other factors, Black people with multiple myeloma had similar or sometimes better survival than white people. The researchers noted that differences in access to treatment may play an important role in outcomes.

However, another study found that non-Hispanic Black people have higher rates of multiple myeloma and death from the disease than other racial and ethnic groups in the United States.

These differences point to an important problem: Not everyone with multiple myeloma has the same access to early diagnosis, specialists, newer treatments, or clinical trials. Barriers related to insurance, cost, location, and the healthcare system can affect the care a person receives.

The Importance of Self-Advocacy

If you’re having trouble getting the care you need, ask your healthcare team for a referral to a multiple myeloma specialist or information about clinical trials. A patient navigator or social worker can also help you navigate insurance, transportation, financial assistance, and other barriers to care.

Advocating for yourself can mean asking questions about your treatment plan, exploring whether newer therapies or clinical trials may be options, and telling your doctor about any side effects or concerns.

Seeking a second opinion is also an option if you want another perspective on your care plan.

References

Read full article

Comments
Questions

View all 60 comments

Diagnosed 10/2015 Stage two high risk. 4 cycles of Velcade/Dex. Could not tolerate revlimid. SCT 3/2016. Ninlaro maintenance 1/2017-2/2021. Currently SCR. Loving the good life!